Acquisition History ATRIN PHARMACEUTICALS was acquired by Aprea Therapeutics in May 2022, indicating potential alignment with larger biotech strategies and possible transition in supplier relationships, licensing opportunities, or ongoing collaboration in DDR pathway programs.

Small Scale Ops With a lean team of 2-10 employees and revenue under one million, ATRIN presents a niche opportunity for CRO/CDMO partnerships, specialized contract manufacturing, or targeted clinical development services to accelerate scale.

DDR Focus ATRIN is positioned in the DNA Damage Response space with emphasis on ATR inhibitors, suggesting sales opportunities around diagnostic collaboration tools, companion diagnostics, and precision oncology partnerships to enhance patient selection.

Strategic Partnerships Past partnerships with Signum-Health and Yes International imply openness to collaborative development programs; identify potential distributors, licensing partners, or research collaborations to expand reach.

Funding Signals Current funding of approximately $1.8M and limited revenue highlight the need for strategic investment, grant support, or joint venture pitches to fund development milestones and bridge to larger partnerships or acquisition.